ALLR FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important November 12 Deadline in Securities Class Action – ALLR

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Allarity Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [2][3]. Group 1: Class Action Details - The class period for the Allarity securities is from May 17, 2022, to July 19, 2024, and the lead plaintiff deadline is November 12, 2024 [2]. - Investors who purchased Allarity securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Case Allegations - The lawsuit alleges that Allarity and its former officers made false and misleading statements regarding the regulatory prospects of their drug candidate Dovitinib [5]. - It is claimed that Allarity engaged in improper conduct related to the Dovitinib new drug application and premarket approval application, leading to increased regulatory scrutiny and potential legal repercussions [5]. - The lawsuit asserts that Allarity downplayed the likelihood of enforcement actions following an investigation into their conduct, resulting in materially false public statements [5].